Stock Events

Stock Events

60 Degrees Pharmaceuticals 

$0.037500
26
+$0.00+5.63% Wednesday 18:47

Statistics

Day High
0.0503
Day Low
0.0375
52W High
0.0375
52W Low
0.0375
Volume
931
Avg. Volume
-
Mkt Cap
158,625
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-4.65
-3.35
-2.04
-0.73
Expected EPS
-0.735
Actual EPS
N/A

Financials

-1,165.25%Profit Margin
Unprofitable
2022
2023
2024
1.36MRevenue
-15.89MNet Income

Analyst Ratings

13.85Average Price Target
The highest estimate is 24.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SXTPW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences is a biopharmaceutical company that competes with 60 Degrees Pharmaceuticals in the development and marketing of treatments for infectious diseases, including those in tropical regions.
Pfizer
PFE
Mkt Cap149.38B
Pfizer is a global pharmaceutical corporation that competes across various therapeutic areas, including infectious diseases, which overlaps with 60 Degrees Pharmaceuticals' focus.
Merck
MRK
Mkt Cap294.03B
Merck & Co. is involved in the discovery, development, manufacturing, and marketing of pharmaceuticals for infectious diseases, directly competing with 60 Degrees Pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the area of infectious diseases, offering treatments that could be alternatives to those developed by 60 Degrees Pharmaceuticals.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie competes in the pharmaceuticals market, including infectious diseases, with a strong emphasis on research and development, making it a competitor to 60 Degrees Pharmaceuticals.
Novartis
NVS
Mkt Cap292.07B
Novartis is a global healthcare company that has a broad portfolio, including treatments for infectious diseases, competing with 60 Degrees Pharmaceuticals.
GSK
GSK
Mkt Cap106.31B
GlaxoSmithKline focuses on pharmaceuticals and vaccines for infectious diseases, directly competing with 60 Degrees Pharmaceuticals in this therapeutic area.
Sanofi
SNY
Mkt Cap105.92B
Sanofi is a global biopharmaceutical company focused on human health, including infectious diseases, making it a competitor to 60 Degrees Pharmaceuticals.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for infectious diseases, competing with 60 Degrees Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca is a global, science-led biopharmaceutical business that operates in various therapeutic areas, including infectious diseases, making it a competitor to 60 Degrees Pharmaceuticals.

About

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Show more...
CEO
Dr. Geoffrey Stuart Dow Ph.D.
Employees
3
Country
United States
ISIN
US83006G1123

Listings

XNAS
US
SXTP
XNAS
US
SXTPW
BOATS
BOATS
SXTP.BOATS

0 Comments

Share your thoughts

FAQ

What is 60 Degrees Pharmaceuticals stock price today?▼
The current price of SXTPW is $0.04 USD — it has increased by +5.63% in the past 24 hours. Watch 60 Degrees Pharmaceuticals stock price performance more closely on the chart.
What is 60 Degrees Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange 60 Degrees Pharmaceuticals stocks are traded under the ticker SXTPW.
What is 60 Degrees Pharmaceuticals market cap?▼
Today 60 Degrees Pharmaceuticals has the market capitalization of 158,625
When is the next 60 Degrees Pharmaceuticals earnings date?▼
60 Degrees Pharmaceuticals is going to release the next earnings report on August 19, 2026.
What were 60 Degrees Pharmaceuticals earnings last quarter?▼
SXTPW earnings for the last quarter are -1.28 USD per share, whereas the estimation was -0.76 USD resulting in a -68.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is 60 Degrees Pharmaceuticals revenue for the last year?▼
60 Degrees Pharmaceuticals revenue for the last year amounts to 1.36M USD.
What is 60 Degrees Pharmaceuticals net income for the last year?▼
SXTPW net income for the last year is -15.89M USD.
How many employees does 60 Degrees Pharmaceuticals have?▼
As of June 18, 2026, the company has 3 employees.
In which sector is 60 Degrees Pharmaceuticals located?▼
60 Degrees Pharmaceuticals operates in the Health & Wellness sector.
When did 60 Degrees Pharmaceuticals complete a stock split?▼
The last stock split for 60 Degrees Pharmaceuticals was on January 20, 2026 with a ratio of 1:4.
Where is 60 Degrees Pharmaceuticals headquartered?▼
60 Degrees Pharmaceuticals is headquartered in Washington, United States.